Skip to content

Study to Improve the Treatment of Epilepsy (SITE)

Study to Improve the Treatment of Epilepsy (SITE). A Randomized Study Comparing Adjustment of Treatment to Reduce Side Effects of Antiepileptic Drugs With Continuing Treatment Unchanged

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00133081
Enrollment
255
Registered
2005-08-22
Start date
2002-10-31
Completion date
2006-08-31
Last updated
2005-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

epilepsy, antiepileptic drugs, side effects, quality of life

Brief summary

The purpose of this study is to assess whether changing antiepileptic medication can reduce side effects and improve the quality of life in patients with epileptic seizures that are well controlled with antiepileptic drugs.

Detailed description

Background. The aim of the treatment with antiepileptic drugs (AEDs) is to achieve seizure freedom without causing side effects. Assessment of side effects is difficult. They may start insidiously, the patient may not associate certain complaints with the use of AEDs, or the treating physician does not take enough time to discuss this topic during the limited time of a visit in the outpatient department. We know from clinical trials that side effects occur in a substantial group of patients. We do not know whether we deal with this possible complication in an adequate way in clinical practice. Study objective. To study whether adjustment of medication will reduce the occurrence of side effects and improve quality of life. Study design. A randomised clinical trial comparing adjustment of treatment in case of relevant side effects to continuing treatment unchanged. Relevant side effects are defined as at least one moderate or serious problem scored on a questionnaire to assess complaints in people with epilepsy. Patients who do not report relevant side effects will be followed for 13 months (arm A) in which two visits are scheduled, after 7 and 13 months respectively. The patients who do report relevant side effects will be randomised to either discussion of the questionnaire results and adjustment of treatment if appropriate (arm B) or to ignore the results of the questionnaire and continue treatment unchanged (arm C). Investigations will be repeated in both groups after 7 and 13 months after the initial visit.

Interventions

DRUGAll registered antiepileptic drugs

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
UMC Utrecht
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years or older * Treatment: antiepileptic drugs for epilepsy * No change in medication during last 6 months * No obvious clinical reason to change medication immediately

Exclusion criteria

* Concurrent disease or disorder that might interfere with the conduct of the study * Inability to comply to the protocol * Impaired intellectual functioning, leading to inability to comply to the protocol and complete the necessary questionnaires

Design outcomes

Primary

MeasureTime frame
Complaints (questionnaire) at 7 and 13 months

Secondary

MeasureTime frame
Quality of Life (Qolie-10) at 7 and 13 months

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026